Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-28T14:59:34.139Z Has data issue: false hasContentIssue false
  • English
  • Français

The NEONATE score predicts freedom from interstage mortality or transplant in a modern cohort

Published online by Cambridge University Press:  28 November 2023

Humera Ahmed Open the ORCID record for Humera Ahmed [Opens in a new window] ,
Jeffrey B. Anderson ,
Katherine E. Bates ,
Carole M. Lannon ,
David W. Brown  and
for the National Pediatric Cardiology Quality Improvement Collaborative
Humera Ahmed*
Affiliation:
Departments of Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Jeffrey B. Anderson
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Katherine E. Bates
Affiliation:
C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, USA
Carole M. Lannon
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
David W. Brown
Affiliation:
Boston Children’s Hospital, Boston, MA, USA
*
Corresponding author: Humera Ahmed; Email: ahmedh5@chop.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Derived from the National Pediatric Cardiology Quality Improvement Collaborative registry, the NEONATE risk score predicted freedom from interstage mortality or heart transplant for patients with single ventricle CHD and aortic arch hypoplasia discharged home following Stage 1 palliation.

Objectives:

We sought to validate the score in an external, modern cohort.

Methods:

This was a retrospective cohort analysis of single ventricle CHD and aortic arch hypoplasia patients enrolled in the National Pediatric Cardiology Quality Improvement Collaborative Phase II registry from 2016 to 2020, who were discharged home after Stage 1 palliation. Points were allocated per the NEONATE score (Norwood type—Norwood/Blalock–Taussig shunt: 3, Hybrid: 12; extracorporeal membrane oxygenation post-op: 9, Opiates at discharge: 6, No Digoxin at discharge: 9, Arch Obstruction on discharge echo: 9, Tricuspid regurgitation ≥ moderate on discharge echo: 12; Extra oxygen plus ≥ moderate tricuspid regurgitation: 28). The composite primary endpoint was interstage mortality or heart transplant.

Results:

In total, 1026 patients met inclusion criteria; 61 (6%) met the primary outcome. Interstage mortality occurred in 44 (4.3%) patients at a median of 129 (IQR 62,195) days, and 17 (1.7%) were referred for heart transplant at a 167 (114,199) days of life. The median NEONATE score was 0(0,9) in those who survived to Stage 2 palliation compared to 9(0,15) in those who experienced interstage mortality or heart transplant (p < 0.001). Applying a NEONATE score cut-off of 17 points that separated patients into low- and high-risk groups in the learning cohort provided 91% specificity, negative predictive value of 95%, and overall accuracy of 87% (85.4–89.5%).

Conclusion:

In a modern cohort of patients with single ventricle CHD and aortic arch hypoplasia, the NEONATE score remains useful at discharge post-Stage 1 palliation to predict freedom from interstage mortality or heart transplant.

Keywords

CHDsingle ventriclepaediatric cardiologyrisk score
Type
Original Article
Information
Cardiology in the Young , First View , pp. 1 - 8
Check for updates
Copyright
© The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Boneva, RS, Botto, LD, Moore, CA, Yang, Q, Correa, A, Erickson, JD. Mortality associated with congenital heart defects in the United States. Circulation 2001; 103: 2376–2381.CrossRefGoogle ScholarPubMed
Tabbutt, S, Ghanayem, NS, Ravishankar, C, et al. Risk factors for hospital morbidity and mortality after the Norwood procedure: a report from the Pediatric Heart Network Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg 2012; 144: 882–895.CrossRefGoogle ScholarPubMed
Ahmed, H, Anderson, JB, Bates, KE, et al. Characteristics of interstage death after discharge from stage I palliation. Pediatr Cardiol 2021; 42: 1372–1378.CrossRefGoogle ScholarPubMed
Ghanayem, NS, Allen, KR, Tabbutt, S, et al. Interstage mortality after the Norwood procedure: results of the multicenter Single Ventricle Reconstruction Trial. J Thorac Cardiovasc Surg 2012; 144: 896–906.CrossRefGoogle ScholarPubMed
Cross, RR, Harahsheh, AS, McCarter, R, et al. Identified mortality risk factors associated with presentation, initial hospitalization, and interstage period for the Norwood operation in a multi-centre registry: a report from the national pediatric cardiology-quality improvement collaborative. Cardiol Young 2014; 24: 253–262.CrossRefGoogle Scholar
Anderson, JB, Beekman, RH, Kugler, JD, et al. Improvement in interstage survival in a national pediatric cardiology learning network. Circ Cardiovasc Qual Outcomes 2015; 8: 428–436.CrossRefGoogle Scholar
Anderson, JB, Iyer, SB, Schidlow, DN, et al. National Pediatric Cardiology Quality Improvement Collaborative. Variation in growth of infants with a single ventricle. J Pediatr 2012; 161: 16–21.CrossRefGoogle ScholarPubMed
Hanke, SP, Joy, B, Riddle, E, et al. Risk factors for unanticipated readmissions during the interstage: a report from the national pediatric cardiology quality improvement collaborative. Semin Thorac Cardiovasc Surg 2016; 28: 803–814.CrossRefGoogle ScholarPubMed
Brown, DW, Mangeot, C, Anderson, J, et al. Digoxin use is associated with reduced IM in patients with no history of arrhythmia after stage I palliation for single ventricle disease. J Am Heart Assoc 2016; 5(1): e002376.CrossRefGoogle Scholar
Oster, ME, Kellerman, M, McCracken, C, Ohye, RG, Mahle, WT. Association of digoxin with IM: results from the pediatric heart network single ventricle reconstruction trial public use dataset. J Am Heart Assoc 2016; 5: e002566.CrossRefGoogle Scholar
Ahmed, H, Anderson, JB, Bates, KE, et al. Development of a validated risk score for interstage death or transplant after stage I palliation for single-ventricle heart disease. J Thorac Cardiovasc Surg 2020; 160: 1021–1030.CrossRefGoogle ScholarPubMed
Klausner, RE, Parra, D, Kohl, K, et al. Impact of digoxin use on interstage outcomes of single ventricle heart disease (from a NPC-QIC registry analysis). Am J Cardiol 2021; 154: 99–105.CrossRefGoogle ScholarPubMed
Batsis, M, Kochilas, L, Chin, AJ, Kelleman, M, Ferguson, E, Oster, ME. Association of digoxin with preserved echocardiographic indices in the interstage period: a possible mechanism to explain improved survival? J Am Heart Assoc 2021; 10: e021443.CrossRefGoogle ScholarPubMed
O’Byrne, ML, Song, L, Huang, J, et al. Trends in discharge prescription of digoxin after Norwood operation: an analysis of data from the Pediatric Health Information System (PHIS) Database. Pediatr Cardiol 2021; 42: 793–803.CrossRefGoogle ScholarPubMed
O’Byrne, ML, Song, L, Huang, J, et al. Attributable mortality benefit of digoxin treatment in hypoplastic left heart syndrome after the Norwood operation: an instrumental variable-based analysis using data from the Pediatric Health Information Systems Database. Am Heart J 2023; 263: 35–45. DOI: 10.1016/j.ahj.2023.05.005.CrossRefGoogle ScholarPubMed